A study from 33 years ago reported that insulin injection therapy was required in 50% of renal transplant recipients who were given high-dose GC therapy [9] while a recent study indicated that nateglinide and acarbose improved postprandial hyperglycemia in patients with GC-DM [10]. The gene discussed is INS; the disease is diabetes mellitus.